ELUVIA™

Drug-Eluting Vascular Stent System

Product Design

The Making of Eluvia

The Eluvia Stent is the first and only drug-eluting technology designed to deliver controlled, localized, low-dose amorphous paclitaxel to the target lesion. Eluvia is built on the Innova Stent platform, which was designed to address the unique challenges of the SFA with the optimal amount of strength, flexibility and fracture resistance. In the IMPERIAL RCT, Eluvia demonstrated a statistically significantly higher primary patency* rate and half the TLR rate compared to Zilver PTX at 12 months.

* 12-Month Kaplan-Meier Estimate Primary Patency Rate 

Product Overview

Product Overview

Advanced drug-eluting technology for PAD.

Button
Clinical Programs

Clinical Programs

Unprecedented clinical data outcomes in the SFA.

Button
Sustained Drug Release

Sustained Drug Release

Delivers paclitaxel when restenosis is most likely.

Button
Top